Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from [177Lu]Lu-DOTATATE Molecular Radiotherapy During Induction Chemotherapy for First-Line Stage 4 High-Risk Neuroblastoma in South African Children: Protocol for a Phase 1 Randomized Controlled Trial (LuDO-SA Trial). Local targets link to admitted publications; unresolved targets remain external evidence.
Challenges for paediatric oncology in Africa
10.1016/s1470-2045(12)70569-7 · External reference
SIOP-PODC adapted risk stratification and treatment guidelines: recommendations for neuroblastoma in low- and middle-income settings
10.1002/pbc.25501 · External reference
Overall survival for neuroblastoma in South Africa between 2000 and 2014
10.1002/pbc.27944 · External reference
Factors associated with recurrence and survival length following relapse in patients with neuroblastoma
10.1038/bjc.2016.302 · External reference
The importance of local control management in high-risk neuroblastoma in South Africa
10.1007/s00383-020-04627-x · External reference
Predictors of differential response to induction therapy in high-risk neuroblastoma: a report from the Children’s Oncology Group (COG)
10.1016/j.ejca.2019.02.003 · External reference
Advances in anti-GD2 immunotherapy for treatment of high-risk neuroblastoma
10.1097/mph.0000000000001369 · External reference
Topotecan-vincristine-doxorubicin in stage 4 high-risk neuroblastoma patients failing to achieve a complete metastatic response to rapid COJEC: a SIOPEN study
10.4143/crt.2016.511 · External reference
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
10.1016/s1470-2045(18)30578-3 · External reference
The radiobiology of human neuroblastoma
10.1016/s0167-8140(85)80029-3 · External reference
Nuclear medicine imaging in neuroblastoma: current status and new developments
10.3390/jpm11040270 · External reference
177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma
10.2967/jnumed.110.085100 · External reference
Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis
10.1007/s00259-013-2510-z · External reference
Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma
10.1016/j.nucmedbio.2008.05.002 · External reference
Molybdenum-99 production in South Africa
10.1007/bf01249633 · External reference
Unresolved reference
External reference
Initial experience with gallium-68 DOTA-Octreotate PET/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma
10.1097/mph.0000000000000411 · External reference
Paediatric molecular radiotherapy: challenges and opportunities
10.1016/j.clon.2020.11.007 · External reference
A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma
10.1007/s00259-020-04741-x · External reference
Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [Lu]Lu-DOTATATE
10.1186/s40658-022-00436-4 · External reference
Feasibility and therapeutic potential of combined peptide receptor radionuclide therapy with intensive chemotherapy for pediatric patients with relapsed or refractory metastatic neuroblastoma
10.1097/rlu.0000000000003577 · External reference
Role of F-AlF-NOTATATE PET/CT in selecting pediatric neuroblastoma candidates for Lu-DOTATATE peptide receptor radionuclide therapy
10.3389/fmed.2025.1615136 · External reference
A phase II trial of a personalized, dose-intense administration schedule of lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma-LuDO-N
10.3389/fped.2022.836230 · External reference
Review: the role of radiolabeled DOTA-conjugated peptides for imaging and treatment of childhood neuroblastoma
10.2174/1874471011666171215093112 · External reference
Phase 3 trial of Lu-Dotatate for midgut neuroendocrine tumors
10.1056/nejmoa1607427 · External reference
Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study
10.1007/s00259-020-04873-0 · External reference
Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients
10.1016/j.ejca.2016.12.013 · External reference
Individualized dosimetry to guide LuTATE therapy in pediatric neuroblastoma
10.1055/s-0045-1812305 · External reference
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: a children’s oncology group and SIOPEN group report on SIOPEN/HR-NBL1
10.2967/jnumed.117.195883 · External reference
Unresolved reference
External reference
What makes clinical research in developing countries ethical? The benchmarks of ethical research
10.1086/381709 · External reference
Unresolved reference
External reference
